The BrIDGs program assists researchers in advancing promising therapeutic agents through late-stage pre-clinical development toward an Investigational New Drug (IND) application and clinical testing. Learn more.
Submit a Pre-Clinical Collaboration Proposal
NCATS is accepting proposals on a rolling basis to collaborate with BrIDGs and TRND program scientists.
Bridging Interventional Development Gaps (BrIDGs)
Find out more about the BrIDGs program and its role in advancing new therapeutics.
BrIDGs offers state-of-the-art expertise and resources for pre-clinical development.
Work with BrIDGs
Learn how to collaborate with the BrIDGs program and access crucial resources.
Why BrIDGs Matters
As of fall 2015, BrIDGs has generated data to support 18 IND applications that have been cleared by the Food and Drug Administration and one clinical trial application cleared by Health Canada. A total of 14 projects have been evaluated in clinical trials. Five BrIDGs-supported agents have been evaluated in Phase II human clinical trials, in which researchers give an experimental therapy to a group of patients to evaluate the effectiveness and safety of a treatment. Third-party organizations have licensed or invested in 10 agents during or after their development by BrIDGs. Learn more about BrIDGs projects.